Products

Product candidates

Cellectis is pioneering robust first-in-class allogeneic CAR T-cell programs that address multiple unmet cancer needs. These programs were designed with simplicity, availability and cost-effectiveness for patients.

Read more
UCARTs

UCARTs are “off-the-shelf” allogeneic product candidates, whose production can be industrialized and thereby standardized with consistent pharmaceutical release criteria, over time and from batch to batch.

Read more

Therapeutic indications

Our product candidates, based on gene-edited allogeneic T-cells that express Chimeric Antigen Receptors, or CARs, seek to harness the power of the immune system to target and eradicate cancer cells.

Read more
Manufacturing

Our comprehensive, scalable, efficient and cost-effective manufacturing process generates highly potent CAR T therapies.

Read more